CLAIM CARD
The next high-yield study for glynac should target the **immune** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.
Evidence grade: exploratory
Contradiction status: none
Publication: 104ef0f2-3c97-42e2-8507-9b6ddf7ebf49
Provenance: Derivation Web chain
Citation Support
source_1Xu 2023source_2Xu 2024source_3Kumar 2020source_4Kumar 2022source_5Kumar 2021